Ruxolitinib

Indications & Dose:

Myelofibrosis

• The starting dose is based on patient’s baseline platelet count:

• Greater than 200 X 109 /L: 20 mg given orally twice daily

• 100 X 109 /L to 200 X 109 /L: 15 mg given orally twice daily

• 50 X 109 /L to less than 100 X 109 /L: 5 mg given orally twice daily

• Monitor complete blood counts every 2 to 4 weeks until doses are stabilized, and then as clinically indicated. Modify or interrupt dosing for thrombocytopenia.

Polycythemia Vera

• The starting dose of is 10 mg given orally twice daily

Contraindications:

None.

Side Effects:

Cautions:

Precautions:

• Thrombocytopenia, Anemia and Neutropenia: Manage by dose reduction, or interruption, or transfusion.

• Risk of Infection: Assess patients for signs and symptoms of infection and initiate appropriate treatment promptly. Serious infections should have resolved before starting therapy.

• Symptom Exacerbation Following Interruption or Discontinuation: Manage with supportive care and consider resuming treatment.

• Risk of Non-Melanoma Skin Cancer: Perform periodic skin examinations.

• Lipid Elevations: Assess lipid levels 8-12 weeks from start of therapy and treat as needed. 

Interaction:

Strong CYP3A4 Inhibitors or Fluconazole:

Warnings:

Adverse Effects:

Lactations:

Special Precautions:

Counselling:

Side Effects Or Adverse Reactions:

Thrombocytopenia and anemia, bruising, dizziness and headache

Patient And Carer Advice: